The Evidence Behind Phase 4: What the Research Shows
Cardiac rehabilitation has one of the strongest evidence bases in all of cardiovascular medicine. Decades of research, spanning large randomised controlled trials, systematic reviews, and meta-analyses involving tens of thousands of patients, have demonstrated its effectiveness at reducing mortality, improving functional fitness, and enhancing quality of life following a cardiac event.
As a BACPR-qualified Clinical Exercise Specialist who has worked in cardiac rehabilitation for over thirty years, I believe passionately that patients, carers, GPs, and commissioners should understand this evidence. Because when you understand what the science shows, the case for ongoing Phase 4 rehabilitation becomes not just compelling, it becomes obvious.
This article summarises the most important research findings, with a particular focus on why Phase 4, the long-term maintenance stage, is not a luxury add-on to the rehabilitation pathway, but an essential part of it.
The Broad Evidence Base for Cardiac Rehabilitation
Before examining Phase 4 specifically, it is worth anchoring the discussion in the broader evidence base. A landmark Cochrane systematic review examining over 14,000 patients across 63 randomised controlled trials found that exercise-based cardiac rehabilitation significantly reduced cardiovascular mortality, hospital readmissions, and healthcare costs, whilst improving quality of life and exercise capacity.
In the UK, NICE guidelines support cardiac rehabilitation following myocardial infarction, and there is growing clinical consensus around its role in heart failure management. The British Association for Cardiovascular Prevention and Rehabilitation (BACPR), of which I am a credentialled member, identifies long-term physical activity maintenance as a core component of the rehabilitation pathway, not an optional extra.
That framing matters. Long-term maintenance is not a bonus phase for the particularly motivated. It is part of what makes cardiac rehabilitation work.
Why the Gains from Phase 3 Fade Without Phase 4
One of the most consistent findings in the cardiac rehabilitation literature is the phenomenon of detraining, the gradual reversal of fitness gains that occurs when structured exercise stops. Studies have repeatedly demonstrated that many of the physiological benefits achieved during Phase 3 rehabilitation begin to decline within weeks to months of ceasing exercise.
This is not a reflection of patient failure. It is simply how human physiology works. Improvements in cardiorespiratory fitness, blood pressure, lipid profiles, and vascular function are all dependent on ongoing physical stimulus. Remove the stimulus, and the adaptations reverse.
This is the fundamental physiological argument for Phase 4. The work done in Phase 3 is enormously valuable, but its benefits are transient unless exercise continues. Phase 4 provides the structure, accountability, and clinical oversight needed to ensure it does.
Cardiorespiratory Fitness and VO₂ Max
Cardiorespiratory fitness, most commonly measured as VO₂ max, or maximal oxygen uptake, is one of the most powerful independent predictors of cardiovascular mortality and all-cause mortality ever identified in the scientific literature. Even modest improvements in VO₂ max translate into meaningful reductions in mortality risk.
Exercise-based cardiac rehabilitation reliably improves VO₂ max. Research published in the European Journal of Preventive Cardiology found that exercise training in cardiac patients improved peak VO₂ by an average of 1.55 mL/kg/min, a clinically meaningful change associated with measurable mortality protection.
Without Phase 4, VO₂ max declines back toward the pre-rehabilitation baseline within months. With Phase 4, it can continue to improve. The difference in long-term prognosis between these two trajectories is significant, and it is one of the most straightforward arguments for ongoing supervised exercise that I make to patients, GPs, and commissioners alike.
Mortality Reduction
Perhaps the most striking evidence for cardiac rehabilitation comes from its impact on survival. Multiple systematic reviews and meta-analyses have demonstrated statistically significant reductions in cardiovascular and all-cause mortality among patients who participate in exercise-based cardiac rehabilitation compared to those who receive usual care alone.
The most recent Cochrane review, updated in 2021, confirmed that exercise-based cardiac rehab reduces both cardiovascular mortality and hospital admissions. Importantly, the evidence also suggests the benefit is dose-dependent: more exercise, sustained over a longer period, is associated with greater risk reduction. This directly supports Phase 4: the longer a patient maintains structured, supervised exercise, the greater the potential survival benefit.
I want to be transparent here: there is ongoing academic discussion about the precise size of the mortality benefit in contemporary clinical practice, particularly in the context of significantly improved pharmacological treatments. The RAMIT trial generated debate in this area. But the direction of the evidence, that exercise helps cardiac patients live longer, has not been seriously challenged. The question has always been one of magnitude, not direction.
Hospital Readmission Rates
Hospital readmissions following cardiac events place an enormous burden on patients, families, and the health system. Research consistently shows that cardiac rehabilitation reduces readmission rates and that this benefit is sustained among patients who continue exercising after their formal programme ends.
For NHS commissioners and Integrated Care Boards, this is a particularly important finding. The cost of a single avoidable hospitalisation, typically several thousand pounds, often exceeds the annual cost of a Phase 4 rehabilitation place many times over. The economic case for investing in Phase 4 is strong, and I would encourage any commissioner reading this to look at the National Audit of Cardiac Rehabilitation (NACR) data on this point.
Quality of Life
Beyond the hard clinical outcomes, there is robust and consistent evidence that cardiac rehabilitation improves health-related quality of life across multiple dimensions, physical function, emotional well-being, social participation, self-efficacy, and the ability to return to work or meaningful activity.
Phase 4 adds something difficult to quantify but enormously important: community. The peer support within a Phase 4 group setting provides a sense of shared experience and mutual encouragement that simply cannot be replicated in a purely clinical context. Patients who attend regularly tell me that the group itself, the friendships formed, the shared challenges and achievements, is often what keeps them coming back. And coming back is everything.
The Evidence Specific to Heart Failure
The HF-ACTION trial, a landmark multicentre randomised controlled trial, provided definitive evidence that exercise training is safe and beneficial for patients with heart failure with reduced ejection fraction (HFrEF), demonstrating improvements in exercise capacity, quality of life, and a trend toward reduced mortality and hospitalisation.
Subsequent research has extended the evidence base to heart failure with preserved ejection fraction (HFpEF), a condition for which effective pharmacological treatments remain limited. Exercise rehabilitation is currently one of the most evidence-supported interventions available for HFpEF patients. For this growing population, Phase 4 is not just helpful. It may be the most impactful intervention available.
What the UK Guidelines Say
The BACPR Standards and Core Components for Cardiovascular Disease Prevention and Rehabilitation explicitly recognise long-term physical activity maintenance as a core component of cardiac rehabilitation. The guidance is clear that rehabilitation should be understood as a lifelong process, not a short-term clinical intervention.
NHS England’s Long Term Plan identifies cardiovascular disease prevention as a priority area. The NACR tracks outcomes across the rehabilitation pathway, and its data consistently highlight the gap between Phase 3 completion and long-term exercise maintenance, a gap that well-run Phase 4 services are uniquely positioned to address.
In my experience, the patients who make the most remarkable long-term recoveries are not necessarily those who had the mildest cardiac events. They are the ones who found a Phase 4 programme they valued, stuck with it, and made regular supervised exercise a non-negotiable part of their life.
Conclusion: The Evidence Is Clear
The research supporting cardiac rehabilitation is extensive, consistent, and compelling. And the case for Phase 4 specifically, the long-term maintenance stage, is grounded in the fundamental physiology of detraining, the dose-dependent nature of exercise benefits, and the evidence that sustained participation reduces mortality, prevents hospitalisation, and transforms quality of life.
If you are a patient who has completed Phase 3 cardiac rehabilitation and is seeking ongoing supervised exercise in Brighton or the surrounding area, I would be delighted to speak with you. If you are a GP or clinician looking to refer a patient to Phase 4, please visit my referrer page or contact me directly.
The science is on our side. Let’s use it.
About the Author: Richard Stantiford MSc, ACSM C-EP, BACPR is a Clinical Exercise Specialist and Specialist Personal Trainer based in Brighton. He is the founder of The Lifestyle Physiologist and has over 30 years of experience working with cardiac patients, stroke survivors, and people with chronic conditions. To learn more or book a free consultation, visit thelifestylephysiologist.com/.
